In this episode, Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss tardive dyskinesia (TD), mood disorders, and antipsychotics. They review current clinical considerations and assessments, including whether antipsychotic prescriptions for mood disorders have increased, if patients with mood disorder are at higher risk for TD and why, and when and how to use an AIMS exam, even in telepsychiatry. They also review the evidence base for VMAT2 inhibitors in TD, what nonevidence-based treatments healthcare professionals should avoid, and how to choose between the 2 VMAT2 inhibitors.  

Presenters:

Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Joseph Goldberg, MD
Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Content based on an online CME program supported by an educational grant from Neurocrine Biosciences.

Link to full program:
https://bit.ly/2RM8hfM